SCHEMBL5151502

SCHEMBL5151502

O=C1CSC(c2cccc3c2OCO3)N1CCc1ccc2c(c1)OCO2

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.47
ALDH1A1 P00352 8/20 0.46
TSHR P16473 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
DPP4 P27487 2/20 0.42
GAA P10253 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HPGD P15428 2/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
DRD3 P35462 1/20 0.42
CMA1 P23946 1/20 0.41
HSD17B10 Q99714 1/20 0.41
USP2 O75604 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155140 0.86 ALDH1A1 (0.49) MGAMALDH1A1TSHRSMN1; SMN2DPP4
SCHEMBL747923 0.80 KMT2A (0.52) MGAMALDH1A1TSHRSMN1; SMN2GAA
SCHEMBL5151414 0.80 ACHE (0.56) MGAMALDH1A1TSHRSMN1; SMN2DPP4
SCHEMBL5152300 0.79 HCRTR1 (0.56) MGAMALDH1A1TSHRSMN1; SMN2GAA
SCHEMBL5156712 0.79 GAA (0.60) ALDH1A1TSHRSMN1; SMN2GAAL3MBTL1
SCHEMBL5156102 0.79 KMT2A (0.48) MGAMALDH1A1L3MBTL1MAPTHPGD
SCHEMBL5156362 0.79 SMN1; SMN2 (0.43) MGAMALDH1A1TSHRSMN1; SMN2GAA
SCHEMBL5149606 0.78 KMT2A (0.50) MGAMALDH1A1L3MBTL1MAPTHPGD
SCHEMBL5151401 0.78 KMT2A (0.50) MGAMALDH1A1GAAL3MBTL1MAPT
SCHEMBL5149502 0.76 MGAM (0.56) MGAMALDH1A1TSHRSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 MGAM 2524/4885ALDH1A1 3381/4885TSHR 2154/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MGAM 3677/4885ALDH1A1 1370/4885TSHR 3944/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MGAM 3677/4885ALDH1A1 1370/4885TSHR 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.